196 related articles for article (PubMed ID: 38799662)
1. Flipping the GPCR Switch: Structure-Based Development of Selective Cannabinoid Receptor 2 Inverse Agonists.
Kosar M; Sarott RC; Sykes DA; Viray AEG; Vitale RM; Tomašević N; Li X; Ganzoni RLZ; Kicin B; Reichert L; Patej KJ; Gómez-Bouzó U; Guba W; McCormick PJ; Hua T; Gruber CW; Veprintsev DB; Frank JA; Grether U; Carreira EM
ACS Cent Sci; 2024 May; 10(5):956-968. PubMed ID: 38799662
[TBL] [Abstract][Full Text] [Related]
2. Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis.
Porter RF; Szczesniak AM; Toguri JT; Gebremeskel S; Johnston B; Lehmann C; Fingerle J; Rothenhäusler B; Perret C; Rogers-Evans M; Kimbara A; Nettekoven M; Guba W; Grether U; Ullmer C; Kelly MEM
Molecules; 2019 Sep; 24(18):. PubMed ID: 31540271
[TBL] [Abstract][Full Text] [Related]
3. Elucidation of partial activation of cannabinoid receptor type 2 and identification of potential partial agonists: Molecular dynamics simulation and structure-based virtual screening.
Uba AI; Aluwala H; Liu H; Wu C
Comput Biol Chem; 2022 Aug; 99():107723. PubMed ID: 35850049
[TBL] [Abstract][Full Text] [Related]
4. Dual allosteric and orthosteric pharmacology of synthetic analog cannabidiol-dimethylheptyl, but not cannabidiol, on the cannabinoid CB
Bouma J; Broekhuis JD; van der Horst C; Kumar P; Ligresti A; van der Stelt M; Heitman LH
Biochem Pharmacol; 2023 Dec; 218():115924. PubMed ID: 37972874
[TBL] [Abstract][Full Text] [Related]
5. Chromenopyrazole-based High Affinity, Selective Fluorescent Ligands for Cannabinoid Type 2 Receptor.
Singh S; Oyagawa CRM; Macdonald C; Grimsey NL; Glass M; Vernall AJ
ACS Med Chem Lett; 2019 Feb; 10(2):209-214. PubMed ID: 30783505
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid type-2 receptor agonist, inverse agonist, and anandamide regulation of inflammatory responses in IL-1β stimulated primary human periodontal ligament fibroblasts.
Abidi AH; Alghamdi SS; Dabbous MK; Tipton DA; Mustafa SM; Moore BM
J Periodontal Res; 2020 Oct; 55(5):762-783. PubMed ID: 32562275
[TBL] [Abstract][Full Text] [Related]
7. 1,2-Dihydro-2-oxopyridine-3-carboxamides: the C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor.
Lucchesi V; Parkkari T; Savinainen JR; Malfitano AM; Allarà M; Bertini S; Castelli F; Del Carlo S; Laezza C; Ligresti A; Saccomanni G; Bifulco M; Di Marzo V; Macchia M; Manera C
Eur J Med Chem; 2014 Mar; 74():524-32. PubMed ID: 24518874
[TBL] [Abstract][Full Text] [Related]
8. Cellular Assay to Study β-Arrestin Recruitment by the Cannabinoid Receptors 1 and 2.
Bouma J; Soethoudt M; van Gils N; Xia L; van der Stelt M; Heitman LH
Methods Mol Biol; 2023; 2576():189-199. PubMed ID: 36152187
[TBL] [Abstract][Full Text] [Related]
9. Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.
Janero DR; Korde A; Makriyannis A
Methods Enzymol; 2017; 593():217-235. PubMed ID: 28750804
[TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects.
Hu SJ; Cheng G; Zhou H; Zhang Q; Zhang QL; Wang Y; Shen Y; Lian CX; Ma XQ; Zhang QY; Qin LP
Molecules; 2022 Jan; 27(3):. PubMed ID: 35163968
[TBL] [Abstract][Full Text] [Related]
11. N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R).
Graziano G; Delre P; Carofiglio F; Brea J; Ligresti A; Kostrzewa M; Riganti C; Gioè-Gallo C; Majellaro M; Nicolotti O; Colabufo NA; Abate C; Loza MI; Sotelo E; Mangiatordi GF; Contino M; Stefanachi A; Leonetti F
Eur J Med Chem; 2023 Feb; 248():115109. PubMed ID: 36657299
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel orthosteric-allosteric ligands of the cannabinoid receptor type 2 (CB
Ferrisi R; Gado F; Polini B; Ricardi C; Mohamed KA; Stevenson LA; Ortore G; Rapposelli S; Saccomanni G; Pertwee RG; Laprairie RB; Manera C; Chiellini G
Front Chem; 2022; 10():984069. PubMed ID: 36238097
[TBL] [Abstract][Full Text] [Related]
13. Platform Reagents Enable Synthesis of Ligand-Directed Covalent Probes: Study of Cannabinoid Receptor 2 in Live Cells.
Kosar M; Sykes DA; Viray AEG; Vitale RM; Sarott RC; Ganzoni RL; Onion D; Tobias JM; Leippe P; Ullmer C; Zirwes EA; Guba W; Grether U; Frank JA; Veprintsev DB; Carreira EM
J Am Chem Soc; 2023 Jul; 145(28):15094-15108. PubMed ID: 37401816
[TBL] [Abstract][Full Text] [Related]
14. Understanding the Dynamics of the Structural States of Cannabinoid Receptors and the Role of Different Modulators.
Manandhar A; Haron MH; Klein ML; Elokely K
Life (Basel); 2022 Dec; 12(12):. PubMed ID: 36556502
[TBL] [Abstract][Full Text] [Related]
15. The Leu/Val
Llinas Del Torrent C; Raïch I; Gonzalez A; Casajuana-Martin N; Lillo J; Rebassa JB; Ferreiro-Vera C; Sánchez de Medina V; Franco R; Navarro G; Pardo L
J Chem Inf Model; 2023 Sep; 63(18):5927-5935. PubMed ID: 37644761
[TBL] [Abstract][Full Text] [Related]
16. Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose.
Zhou H; Peng Y; Halikhedkar A; Fan P; Janero DR; Thakur GA; Mercier RW; Sun X; Ma X; Makriyannis A
ACS Chem Neurosci; 2017 Jun; 8(6):1338-1347. PubMed ID: 28220706
[TBL] [Abstract][Full Text] [Related]
17. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.
Ragusa G; Gómez-Cañas M; Morales P; Rodríguez-Cueto C; Pazos MR; Asproni B; Cichero E; Fossa P; Pinna GA; Jagerovic N; Fernández-Ruiz J; Murineddu G
Eur J Med Chem; 2017 Feb; 127():398-412. PubMed ID: 28088085
[TBL] [Abstract][Full Text] [Related]
18. Two Affinity Sites of the Cannabinoid Subtype 2 Receptor Identified by a Novel Homogeneous Binding Assay.
Martínez-Pinilla E; Rabal O; Reyes-Resina I; Zamarbide M; Navarro G; Sánchez-Arias JA; de Miguel I; Lanciego JL; Oyarzabal J; Franco R
J Pharmacol Exp Ther; 2016 Sep; 358(3):580-7. PubMed ID: 27358483
[TBL] [Abstract][Full Text] [Related]
19. Structure-kinetic relationship studies of cannabinoid CB
Soethoudt M; Hoorens MWH; Doelman W; Martella A; van der Stelt M; Heitman LH
Biochem Pharmacol; 2018 Jun; 152():129-142. PubMed ID: 29574067
[TBL] [Abstract][Full Text] [Related]
20. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.
Prather PL; FrancisDevaraj F; Dates CR; Greer AK; Bratton SM; Ford BM; Franks LN; Radominska-Pandya A
Biochem Biophys Res Commun; 2013 Nov; 441(2):339-43. PubMed ID: 24148245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
